Driven by cutting edge science, zPREDICTA offers services for screening anti-cancer therapeutic agents.
Our unique multi-component organ-specific extracellular matrix (ECM) enables accurate reconstruction of human tissue architecture driving accurate prediction of clinical outcomes.
Available models: bone marrow, breast, colon, lung, prostate, ovary, stomach.
Available indications: AML, multiple myeloma
Available tissues: bone marrow, breast, colon, lung, ovary, prostate, stomach, etc.
Available format(s): 96-well
(384-well in development)
Compatible with all standard readout methods: flow cytometry, RNAseq, in situ imaging, high content imaging, CellTiter Glo, MTS, and other readouts in your workflow.
Our team of expert scientists is ready to create custom models for any tissue of interest.
Add the extracellular matrix (ECM) mimicking the basement membrane or bone endosteum to the plate to create a thin coating.
Mix cells with organ-specific ECM. Reconstructed Organ platform is compatible with multiple cell types from tumor and healthy tissues including epithelium, stroma, endothelium, and immune cells.
Add the cell/ECM mixture to the pate. Once polymerized it creates a 1mm semi-solid layer.
Overlay the cell/ECM layer with growth medium containing disease-specific factors.
Add therapeutic agents either alone or in combinations. The system is compatible with multiple drug classes including small molecules, antibodies, antibody-drug conjugates (ADC), cellular and immunotherapies, such as CAR-T, etc.
After culture, cellular behavior can be evaluated directly in-matrix or cells can be isolated from the ECM for downstream analysis.
For more information, please .
To set-up a project please complete the appropriate Project Information Form above and .
For more information on the End-of-the-Year promotion or the HTS Pilot Program, please .